AI PM in Healthcare: Navigating FDA & Regulatory Interviews

The candidates who understand clinical workflows rarely get called back. The ones who pass — know how regulatory strategy is product strategy. At Verily’s Q2 hiring committee, a candidate was rejected not because they misstated 21 CFR Part 11, but because they treated the FDA submission as a compliance milestone, not a product design lever. In healthcare AI, your roadmap doesn’t start with user stories — it starts with predicate devices.

AI PMs hired at Tempus and Verily in the last 18 months shared one trait: they framed algorithmic validation as a go-to-market dependency, not a technical detail. They didn’t recite FDA pathways — they mapped them to clinical adoption curves. Two failed interviews this year at Verily cited “strong technical background” but were downgraded because the candidate positioned regulatory approval as a gate, not a feedback loop.

This isn’t about passing an interview. It’s about proving you can build products where a false positive isn’t a UX flaw — it’s a reportable event.

Who This Is For

You’re a product manager with 3–7 years in tech, possibly in AI/ML, moving from consumer or enterprise into healthcare. You’ve read FDA whitepapers but have never submitted a 510(k). You’ve interviewed at Verily, Tempus, or an AI-health startup, and were told you “lacked domain depth.” You’re not being tested on memorization — you’re being assessed for judgment under uncertainty, where clinical risk, liability, and real-world evidence intersect. This isn’t for clinicians pivoting to PM, nor for fresh MBAs. It’s for operators who can translate between FDA reviewers, data scientists, and chief medical officers — in the same meeting.

How Do AI PMs Actually Use FDA Regulations in Product Design?

Most candidates treat regulatory requirements as a checklist. At Tempus, in a recent debrief, a hiring manager said: “They listed SaMD categories correctly, but didn’t connect Class II to our reimbursement strategy.” That’s the failure pattern: not ignorance, but irrelevance.

The successful candidate redesigns the product timeline around predicate selection. At Verily’s 2023 review for a diabetic retinopathy AI tool, the PM didn’t wait for algorithm validation to start the regulatory path — they chose a predicate device before finalizing the model architecture. Why? Because the predicate determined whether they needed a De Novo or 510(k) pathway, which set the required clinical study size, which impacted the data procurement budget by $1.8M.

Regulatory isn’t downstream — it’s upstream of data labeling. Not a compliance task, but a scoping mechanism.

One PM at Tempus reduced their FDA submission risk by narrowing the intended use statement from “detection of non-small cell lung cancer” to “prioritization of high-suspicion nodules for radiologist review.” That pivot — from diagnostic to triage — moved the product from Class III to Class II, cutting review time from 240 to 150 FDA days.

Judgment signal: When asked about your roadmap, do you mention predicate devices, performance thresholds, or real-world validation plans? If not, you’re not speaking the language of healthcare AI PMs.

What’s the Difference Between a Tech PM and an AI Healthcare PM in Practice?

A tech PM optimizes for engagement. An AI healthcare PM optimizes for attributable clinical action. At a Verily post-mortem on a paused sepsis prediction project, the issue wasn’t model accuracy (AUC 0.89) — it was that the alert didn’t change physician behavior in 68% of cases. The PM had treated clinician adoption as a change-management problem, not a product design failure.

In enterprise AI, a model drift of 15% triggers a retrain. In healthcare, that same drift requires a new clinical validation study if it crosses FDA-defined performance bounds. At Tempus, a colorectal cancer biomarker model was held back for 11 weeks because a 12% drop in sensitivity on a new patient cohort triggered a protocol amendment — not a data science issue, but a regulatory one.

The key contrast: consumer PMs ship and iterate. Healthcare PMs must predict iteration cost before shipping. Not iteration speed, but iteration risk.

One candidate at Verily passed because they described their monitoring plan in terms of “pre-specified performance degradation thresholds,” not “feedback loops.” They used the phrase “post-market surveillance protocol” unprompted. That’s the signal: you don’t retrofit compliance — you bake it into the product spec.

Another contrast: in tech, your KPI is adoption. In healthcare AI, your KPI is clinical utility — defined as “measurable improvement in patient outcomes attributable to the product.” At a Tempus interview, a candidate was dinged for saying “our model increased oncologist efficiency.” The hiring manager noted: “Efficiency isn’t a clinical outcome. Survival rate, treatment accuracy, stage at diagnosis — those are outcomes.”

Not output, but impact. Not usage, but attribution.

How Do You Prepare for a Regulatory-Focused Interview at Verily or Tempus?

Most candidates study FDA guidance documents. That’s table stakes. The ones who fail do so because they can’t operationalize them. The ones who win tie regulatory steps to product trade-offs.

At a Verily interview in April, a candidate was asked how they’d prioritize features for an AI-powered ECG analyzer. They responded: “We’d lock the arrhythmia detection module first because it’s our highest-risk component — it maps to a Class II SaMD pathway with a clear predicate. Atrial fibrillation detection has 14 predicate devices; ST-segment analysis has zero — so we’d delay that to v2.”

That answer surfaced three things: risk segmentation, predicate availability, and roadmap sequencing — all framed as product decisions.

Another candidate was asked about handling a model update. They didn’t say “A/B test it.” They said: “We’d assess whether the update triggers a new submission based on FDA’s 2023 AI/ML action plan. A weight update under 5% distributional shift? Probably not. A new input modality, like adding patient age as a feature? That’s a new indication — likely requires a new 510(k).”

That’s the level of precision expected.

Interviewers aren’t looking for lawyers — they’re looking for PMs who treat regulatory boundaries as design constraints, like latency or cost.

Work through a structured preparation system (the PM Interview Playbook covers AI healthcare regulatory decision trees with real debrief examples from Verily, Tempus, and Pear Therapeutics).

What Does the Real Interview Process Look Like at Verily and Tempus?

Verily’s AI PM interview has 5 stages: recruiter screen (30 min), hiring manager (60 min), technical deep dive (75 min), cross-functional role-play (90 min), and hiring committee. Tempus runs a 4-stage variant: phone screen, case interview, panel with clinical + regulatory leads, then executive alignment.

At Verily, the technical deep dive isn’t about coding — it’s about model lifecycle governance. In Q1 2024, a candidate was asked to design a monitoring plan for an AI-based depression screener. The right answer included: performance metrics (sensitivity/specificity by demographic strata), drift detection (KS test thresholds), and escalation paths — not just to engineers, but to the quality unit.

The cross-functional role-play is where most fail. You’re given a scenario: “The FDA requests additional validation data on your AI pathology tool for Black patients, citing underrepresentation.” You must negotiate between the CTO (who says “retrain the model”), the CMO (who insists on a new clinical study), and legal (who warns of submission delays).

One candidate lost points by saying “let’s do a quick retrain.” The debrief note: “Didn’t recognize that performance disparity in a regulated product isn’t a data problem — it’s a bias validation requirement under FDA’s diversity guidance.”

At Tempus, the panel interview includes a real-time review of a mock 510(k) summary. You’re handed a one-pager and asked: “What’s missing?” In March, the document omitted the reference standard methodology. The candidate who spotted it — and explained that without a validated ground truth process, analytical validity can’t be established — moved to offer stage.

The hiring committee doesn’t read your resume. They read the interviewer scorecards. And the top comment? “Did they treat regulatory as a core product function?”

Preparation Checklist

  • Map your past product work to SaMD classes (I, II, III) — even if not in healthcare. If you worked on a fraud detection model, frame it as Class I equivalent: low risk, no clinical impact.
  • Internalize the FDA’s 2023 AI/ML Action Plan — not the PDF, but the implications. For example: pre-specification and algorithm change protocols are now expected in submissions.
  • Practice talking about model updates in regulatory terms: “material change,” “supplement vs. new submission,” “lock-and-step” processes.
  • Study 5–10 real 510(k) clearances for AI products — not to memorize, but to reverse-engineer intended use statements. Notice how “assist” vs. “diagnose” changes the class.
  • Prepare 2 stories where you balanced speed and risk — one where you moved fast, one where you slowed down for validation. In healthcare, both must be defensible.
  • Work through a structured preparation system (the PM Interview Playbook covers AI healthcare regulatory decision trees with real debrief examples from Verily, Tempus, and Pear Therapeutics).

You’re not being hired to execute — you’re being hired to decide. Your preparation must reflect that.

Mistakes to Avoid

  1. Treating the FDA as a Gate, Not a Design Partner
    Bad: “We’ll build the MVP, then figure out the submission.”
    Good: “We selected a predicate device with a 120-day average review time to align with our Q4 launch.”
    In a Verily debrief, a candidate said, “Regulatory will tell us what to do.” That’s delegation, not ownership. The FDA isn’t a checkpoint — it’s a stakeholder with enforceable requirements. Your roadmap must anticipate their questions, not react to them.

  2. Talking About Accuracy Without Context
    Bad: “Our model achieved 94% accuracy.”
    Good: “We targeted 88% sensitivity with ≥90% NPV to meet the FDA’s performance threshold for rule-out use in low-prevalence populations.”
    At Tempus, a candidate cited AUC like it was a universal metric. The interviewer responded: “AUC doesn’t appear in FDA submissions. Why are you leading with it?” Clinical performance must be defined by use case — screening, diagnosis, monitoring — and tied to patient risk.

  3. Ignoring Post-Market Requirements
    Bad: “After launch, we’ll monitor performance and fix issues.”
    Good: “Our post-market plan includes quarterly performance reports to the FDA, with automatic escalation if specificity drops below 85% in any demographic cohort.”
    In 2023, Verily delayed a product launch because the PM hadn’t budgeted for post-market surveillance. The hiring manager said: “If you don’t plan for phase IV, you don’t understand the lifecycle.” Real-world performance isn’t optional — it’s a regulatory obligation.

The book is also available on Amazon Kindle.

Need the companion prep toolkit? The PM Interview Prep System includes frameworks, mock interview trackers, and a 30-day preparation plan.

About the Author

Johnny Mai is a Product Leader at a Fortune 500 tech company with experience shipping AI and robotics products. He has conducted 200+ PM interviews and helped hundreds of candidates land offers at top tech companies.

FAQ

Do I need a medical or regulatory background to get hired But you must demonstrate that you’ve learned how clinical risk shapes product decisions. One candidate without a healthcare background was hired at Tempus because they reverse-engineered 8 FDA clearances and mapped the intended use statements to business models. Domain curiosity, not credentials, is the filter.

How much technical depth is expected on AI/ML models?

You won’t be asked to derive backpropagation. But you must speak fluently about validation methods (train/validation/test splits aren’t enough — you need temporal and institutional splits), bias detection (not just demographic parity, but clinical impact disparity), and model cards. At Verily, a candidate failed by saying “we used F1 score.” The interviewer replied: “F1 isn’t clinically interpretable. Why not positive predictive value?”

Is the process different at startups vs. Verily or Tempus?

Yes. Startups expect you to be the regulatory function. At a Series B AI radiology company, one PM wrote their own 510(k) summary. Verily and Tempus have dedicated teams — but they expect you to partner with them as a peer, not a client. The difference isn’t responsibility, but leverage. You’re not doing the work — you’re owning the outcome.

Related Reading